

Long-Term, Real-World Safety and Efficacy of Tenzeligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan

Kadowaki, T., Haneda, M., Ito, H. et al. Adv. Ther (2019)

- [3-year] Long-term post-marketing surveillance (RUBY), to obtain, real-world evidence regarding, the safety and efficacy of teneligliptin, in more than 10,000 patients was conducted in Japan.
- Patient's renal function across categories of estimated glomerular filtration rate (G1-G5) and dialysis were recorded.
- ADRs occurred in 412 patients (3.85%) and were serious in 117 patients (1.09%). The most frequent ADR class was gastrointestinal disorders (0.68%), which included constipation.
- Reduction in HbA1c was sustained for 3 years after starting teneligliptin.

No new safety or efficacy concerns about teneligliptin used in long-term, real-world, clinical settings in patients with T2DM with any stages of renal impairment.